Nika Pharmaceuticals, Inc (NIKA) — SEC Filings
Nika Pharmaceuticals, Inc (NIKA) — 17 SEC filings. Latest: 10-K (Mar 25, 2026). Includes 7 8-K, 6 10-Q, 3 10-K.
View Nika Pharmaceuticals, Inc on SEC EDGAR
Overview
Nika Pharmaceuticals, Inc (NIKA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: NIKA PHARMACEUTICALS, INC. (NIKA) reported a net loss of $76,398 for the fiscal year ended December 31, 2025, a 20.25% improvement from the $95,792 net loss in 2024. General and Administrative expenses increased by 50.75% to $53,026 in 2025 from $35,174 in 2024, while professional fees decreased by
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 3 bearish, 14 neutral. The dominant filing sentiment for Nika Pharmaceuticals, Inc is neutral.
Filing Type Overview
Nika Pharmaceuticals, Inc (NIKA) has filed 3 10-K, 6 10-Q, 1 10-Q/A, 7 8-K with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of NIKA's 17 recent filings, 3 were flagged as high-risk, 3 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$76,398 |
Key Executives
- Dimitar Slavchev Savov
- Clifford P. Redekop
- Clifford Redekop
- Phil E. Ray
- A. Terry Ray
Industry Context
NIKA Pharmaceuticals operates in the pharmaceutical and dietary supplement sectors, focusing on exclusive rights agreements for products like TNG, Carotilen, and Physiolong. The industry is characterized by high R&D costs, stringent regulatory hurdles, and competitive market dynamics. Success often hinges on product innovation, effective marketing, and securing distribution channels.
Top Tags
financials (5) · pharmaceuticals (5) · 10-Q (4) · acquisition (4) · Pharmaceuticals (3) · Biotechnology (3) · Going Concern (3) · OTC Markets (3) · auditor-change (3) · corporate-action (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $76,398 | for the year ended December 31, 2025, a 20.25% decrease from 2024 |
| Accumulated Deficit | $9,004,009 | as of December 31, 2025, indicating significant historical losses |
| General and Administrative Expenses | $53,026 | for the year ended December 31, 2025, a 50.75% increase from 2024 |
| Professional Fees | $23,372 | for the year ended December 31, 2025, a 61.44% decrease from 2024 |
| Net Cash Used in Operating Activities | $79,654 | for the year ended December 31, 2025, a decrease from $154,932 in 2024 |
| Common Stock Shares Outstanding | 1,047,549,224 | as of December 31, 2025 and March 9, 2026 |
| Preferred Stock Shares Outstanding | 15,000,000 | as of December 31, 2025 |
| Revenue | $0 | No revenue generated for the three and nine months ended September 30, 2025 and 2024. |
| Net Loss (9 months) | $(39,309) | Net loss for the nine months ended September 30, 2025, an improvement from $(83,340) in 2024. |
| Cash | $6,287 | Cash balance as of September 30, 2025, up from $2,083 at December 31, 2024. |
| Loans from Nika Europe, Ltd. | $45,000 | Amount advanced to the company by Nika Europe, Ltd. during the nine months ended September 30, 2025. |
| Due to CEO Dimitar Slavchev Savov | $205,164 | Total amount due to the CEO as of September 30, 2025, for advanced operating expenses. |
| Common Shares Outstanding | 1,039,836,001 | Number of common shares outstanding as of November 7, 2025. |
| Net Loss (3 months) | $(7,999) | Net loss for the three months ended September 30, 2025, an improvement from $(8,367) in 2024. |
| Total Operating Expenses (9 months) | $39,309 | Total operating expenses for the nine months ended September 30, 2025, down from $83,340 in 2024. |
Frequently Asked Questions
What are the latest SEC filings for Nika Pharmaceuticals, Inc (NIKA)?
Nika Pharmaceuticals, Inc has 17 recent SEC filings from Feb 2024 to Mar 2026, including 7 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NIKA filings?
Across 17 filings, the sentiment breakdown is: 3 bearish, 14 neutral. The dominant sentiment is neutral.
Where can I find Nika Pharmaceuticals, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nika Pharmaceuticals, Inc (NIKA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nika Pharmaceuticals, Inc?
Key financial highlights from Nika Pharmaceuticals, Inc's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NIKA?
The investment thesis for NIKA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nika Pharmaceuticals, Inc?
Key executives identified across Nika Pharmaceuticals, Inc's filings include Dimitar Slavchev Savov, Clifford P. Redekop, Clifford Redekop, Phil E. Ray, A. Terry Ray.
What are the main risk factors for Nika Pharmaceuticals, Inc stock?
Of NIKA's 17 assessed filings, 3 were flagged high-risk, 3 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Nika Pharmaceuticals, Inc?
Forward guidance and predictions for Nika Pharmaceuticals, Inc are extracted from SEC filings as they are enriched.